– Published by the CML Advocates Network –

The 2020 summary is based on the article "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia", published in the medical journal Leukemia Hochhaus, A., Baccarani, M., Silver, R.T. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966–984 (2020). https://doi.org/10.1038/s41375-020-0776-2
 
Full and final editorial content is wholly and entirely the responsibility of the CML Advocates Network, hosted by the Leukemia Patient Advocates Foundation. Project management, translation costs, and printing were funded through an unrestricted educational grant from Pfizer Inc. to the CML Advocates Network. CML Advocates Network is additionally a recipient of unrestricted funding from Pfizer (and other corporate life-sciences companies) for its CML Horizons Congress, Community Advisory Board and Patient Registry.
 
We would like to express our gratitude to all collaborators involved in the development of this patient-friendly summary 2020. Authorship and ownership of this document rest solely with the CML Advocates Network.